Abstracts tagged "classification criteria"

Abstract Number: 1363 • ACR Convergence 2021
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA
Pascal Richette¹, Marijn Vis², Sarah Ohrndorf³, William Tillett⁴, Marlies Neuhold⁵, Michel van Speybroeck⁶, Elke Theander⁷, Wim Noel⁸, May Shawi⁹, Alexa Kollmeier¹⁰ and Alen Zabotti¹¹, ¹Lariboisiere Hospital, Paris, France, ²Erasmus MC, Badhoevedorp, Netherlands, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Janssen-Cilag, Zug, Switzerland, ⁶Janssen Pharmaceutica, Belgium, Belgium, ⁷Janssen Cilag, Lund, Sweden, ⁸Janssen Pharmaceutica, Vilvoorde, Belgium, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Janssen Research & Development, LLC, La Jolla, CA, ¹¹University of Udine, Udine, Italy
Background/Purpose: Psoriatic arthritis (PsA) is mainly described based on the individual domains or clinical components of the disease.1,2 The aim of this post hoc analysis…
Abstract Number: 0250 • ACR Convergence 2021
Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
Maria Martha Katsicas¹, Maria Cecilia Bertinotti² and Maria Giselle Villarreal², ¹Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina, ²Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile SpA (JSpA) involve enthesitis related arthritis (ERA), juvenile psoriatic arthritis and undifferentiated arthritis (UA) according to the ILAR criteria. Two different patterns have…
Abstract Number: 1403 • ACR Convergence 2021
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Rafael B. Melero-González⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Joaquín M. Belzunegui¹⁰, Clara Moriano¹¹, Julio Sánchez¹², Judit Lluch¹³, Itziar Calvo¹⁴, Vicente Aldasoro¹⁵, Leticia León-Mateos¹⁶, Javier Loricera García¹⁷, Alberto Ruíz-Román⁵, Cristina Valero-Martínez¹⁸, Patricia Moya¹⁹, Marina Tortosa-Cabañas²⁰, Vanessa A. Navarro-Angeles⁶, Carles Galisteo²¹, Anne Riveros-Frutos²², Jose A. Román-Ivorra²³, Selene Labrada-Arrabal²⁴, Margarida Vasques-Rocha²⁵, Carlota L. Iñiguez-Ubiaga²⁶, María García-González²⁷ and Ricardo Blanco²⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁶Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario de La Princesa, Madrid, Spain, ¹⁹Hospital Sant Pau, Barcelona, Spain, ²⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ²¹Hospital Universitari Parc Tauli, Saadell, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁴Hospital del Mar, Barcelona, Spain, ²⁵Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁷Hospital Universitario de Canarias, La Laguna, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
Abstract Number: 0333 • ACR Convergence 2021
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Chi Chiu Mok¹, Yuen Kwan Chung², Carolyn Lee³, Ling Yin Ho⁴ and Chi Hung To², ¹Tuen Mun Hospital, Hong Kong, China, ²Pok Oi Hospital, Hong Kong, Hong Kong, ³Hospital Authority, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To validate the 2019 EULAR/ACR classification criteria for SLE in Hong Kong Chinese patients and compare its performance with the 2012 Systemic Lupus International…
Abstract Number: 1733 • ACR Convergence 2021
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
Martin Aringer¹, Ian N. Bruce², Richard Furie³, Eric Morand⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁷, ¹University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Ege Sinan Torun¹, Erdem Bektaş¹, Fatih Kemik², Murat Bektaş³, Cigdem Cetin⁴, Yasemin Yalcinkaya⁴, Bahar Esen⁴, Ahmet Gül⁵ and Murat Inanc⁶, ¹Istanbul University Istanbul Faculty of Medicine, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁶Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Marijn Vis¹, Pascal Richette², Ramirez Julio³, Marlies Neuhold⁴, Robert Wapenaar⁵, Elke Theander⁶, Wim Noel⁷, May Shawi⁸, Alexa Kollmeier⁹ and William Tillett¹⁰, ¹Erasmus MC, Badhoevedorp, Netherlands, ²Lariboisiere Hospital, Paris, France, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Janssen-Cilag, Zug, Switzerland, ⁵Janssen-Cilag BV, Breda, Netherlands, ⁶Janssen Cilag, Lund, Sweden, ⁷Janssen Pharmaceutica, Vilvoorde, Belgium, ⁸Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
Abstract Number: 0348 • ACR Convergence 2021
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴, Zahi Touma⁵ and Sindhu Johnson⁶, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: We recently demonstrated that a EULAR/ACR classification Criteria score ≥ 20 predicts a higher disease activity throughout the first 5 years after diagnosis. Given…
Abstract Number: 1882 • ACR Convergence 2021
Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
Tannaz Kermani¹, Jason Springer², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of California Los Angeles, Los Angeles, CA, ²Vanderbilt University Medical Center, Franklin, TN, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Health Informatics Institute, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: To compare the clinical characteristics and determine the reliability of a self-reported diagnosis of giant cell arteritis (GCA) or Takayasu’s arteritis (TAK) from an…
Abstract Number: 0349 • ACR Convergence 2021
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
Jessica English¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
Abstract Number: 1888 • ACR Convergence 2021
Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
Gözde Kübra Yardımcı¹, Bayram Farisogulları², Gizem Ayan¹, Levent Kilic¹, Sule Apraş Bilgen¹ and Omer Karadag³, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, ³Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
Abstract Number: 0355 • ACR Convergence 2021
Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus
Noah Forrest¹, Kathryn Jackson², Al'ona Furmanchuk², Anika Ghosh², Jennifer Pacheco², Vesna Mitrovic², Abel Kho², Rosalind Ramsey-Goldman² and Theresa Walunas², ¹Feinberg School of Medicine, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by a heterogenous clinical phenotype that may present differently over time and between patients, which…
Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Xenofon Baraliakos¹, Roberto Ranza², Andrew Ostor³, Francesco Ciccia⁴, Laura Coates⁵, Simona Rednic⁶, Jessica Walsh⁷, Tianming Gao⁸, Apinya Lertratanakul⁸, In-Ho Song⁸, Fabiana Ganz⁸, Kevin Douglas⁸ and Atul Deodhar⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ³Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁴University of Campania Luigi Vanvitelli, Napoli, Italy, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸AbbVie Inc., North Chicago, IL, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
Abstract Number: 0652 • ACR Convergence 2021
Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic
Mmoloki Mathake¹, Julia Murdoch², Andrew Taylor³, Jean-Louis deSousa², Kathy Jao², Rachel Li² and Helen Keen⁴, ¹Fiona Stanley Hospital, Beckenham, Australia, ²Royal Perth Hospital, Perth, Australia, ³Fiona Stanley Hospital, Murdoch, Australia, ⁴Fiona Stanley Hospital, Perth, Australia
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis, and may be associated with irreversible blindness(1). It is therefore essential to make…
Abstract Number: 0804 • ACR Convergence 2021
Validation of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis (RA) in a Nursing-led Triage Clinic
Ching Man Tsang¹, Chi Chiu Mok², Kar Li Chan³, Sau Mei TSE¹ and Ling Yin Ho¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong
Background/Purpose: To shorten the waiting time to see rheumatologists, a nurse-led triage clinic was established in our hospital in September 2018 to triage new referrals…

« Previous Page
1
…
3
4
5
6
7
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].